Apogee Therapeutics, Inc. (APGE)

Current Report Filed: 2026-04-24

Two board members (Andrew Gottesdiener, M.D. and Peter Harwin) are resigning effective May 11, 2026, reducing the board from nine to seven directors, which may signal internal restructuring or strategic shifts.
The company explicitly states the resignations are not due to disagreement on operations, policies, or practices, suggesting these are planned departures rather than contentious exits.
The board reduction to seven directors is a significant change in governance structure that could impact decision-making speed and oversight capabilities at the company.

Insider Trading Filed: 2026-04-10

Insider Michael Henderson, the CEO, sold a total of 20,000 shares of Apogee Therapeutics (APGE) on April 8, 2026, suggesting potential profit-taking.
The shares were sold at weighted average prices of $82.48 and $83.26, indicating the sales were executed at favorable market prices.
The sale reduced Henderson's direct beneficial ownership in the company from 1,135,187 shares to 1,132,987 shares, still maintaining a significant position.

Insider Trading Filed: 2026-04-03

Insider Jane Henderson, the Chief Financial Officer, sold a total of 2,000 shares of Apogee Therapeutics, Inc. (APGE) on April 1, 2026 at weighted average prices of $84.46 and $85.46.
The sale was executed pursuant to a pre-arranged 10b5-1 trading plan, indicating potential financial planning or diversification motives rather than a bearish sentiment.
Henderson still holds a substantial position of 177,371 shares, suggesting continued confidence in the company's long-term prospects.

Insider Trading Filed: 2026-04-03

Insider Carl Dambkowski, the Chief Medical Officer, exercised 4,125 stock options and sold 5,500 shares of Apogee Therapeutics, Inc. (APGE) on April 1, 2026, generating over $465,000 in proceeds.
The stock sales were conducted pursuant to a 10b5-1 trading plan, indicating the transactions were pre-planned and not opportunistic.
Dambkowski continues to hold a significant direct ownership stake of 208,398 shares, representing his continued commitment to the company.

Insider Trading Filed: 2026-03-27

The reporting person, Jane Pritchett Henderson, is the Chief Financial Officer of Apogee Therapeutics, Inc. and has sold 2,000 shares of common stock on March 25, 2026.
The shares were sold at $85 per share, which is within the normal trading range for the stock.
The reporting person still beneficially owns 179,371 shares of Apogee Therapeutics' common stock, indicating they maintain a significant ownership position in the company.

Current Report Filed: 2026-03-25

Apogee Therapeutics, Inc. has successfully raised $377.4 million through a public offering, which will provide additional capital to support the company's operations and drug development pipeline.
The company has granted the underwriters an option to purchase an additional 750,000 shares, which they have exercised in full, indicating strong investor demand for Apogee's stock.
The proceeds from the offering are expected to strengthen Apogee's financial position and enable the company to advance its drug candidates through clinical trials and towards potential commercialization.

Current Report Filed: 2026-03-23

Apogee Therapeutics announced positive maintenance data from the Phase 2 APEX clinical trial of its lead drug candidate zumilokibart (APG777) for atopic dermatitis, showing durable efficacy and tolerability over 52 weeks.
The company plans to initiate Phase 3 trials of zumilokibart in the second half of 2026, aiming for a potential commercial launch in 2029 in what it believes could be a $50 billion atopic dermatitis market.
Apogee also expects to report data from a Phase 1b head-to-head trial of its dual antibody candidate APG279 versus DUPIXENT in moderate-to-severe atopic dermatitis in the second half of 2026.

Insider Trading Filed: 2026-01-22

Fairmount Funds Management LLC, a 10% owner of Apogee Therapeutics, Inc. (APGE), has sold 1.75 million shares of common stock at $76.30 per share.
Tomas Kiselak and Peter Harwin, directors of Apogee Therapeutics, each own 51,166 shares of common stock indirectly through Fairmount Healthcare Fund II LP.
Fairmount Healthcare Fund II LP owns 6,743,321 shares of non-voting common stock, which can be converted to common stock subject to a 9.99% ownership limit.

Insider Trading Filed: 2026-01-16

Insider Michael Henderson sold a significant number of Apogee Therapeutics shares (over 19,000 shares) on January 14, 2026 through a pre-planned 10b5-1 trading plan.
The sales were executed at high prices, with a weighted average price range of $78.64 to $83.79 per share, suggesting Henderson may have been locking in gains.
As CEO, Henderson's insider selling could potentially signal a lack of confidence in the company's near-term prospects, which investors may want to further investigate.

Current Report Filed: 2026-01-06

Apogee Therapeutics announced positive interim data from the Phase 1b clinical trial of its lead drug candidate zumilokibart (APG777) in patients with mild-to-moderate asthma, including favorable safety profile and robust suppression of FeNO, a key biomarker of Type 2 inflammation.
The company reported upcoming 2026 milestones, including data readouts from the Phase 2 APEX trial in atopic dermatitis and initiation of a Phase 3 trial in AD, potentially enabling a launch in 2029.
Apogee confirmed it believes it has sufficient cash runway to fund operations into the second half of 2028, providing visibility on the company's financial position to advance its pipeline.

Important Information